Add office photos
Employer?
Claim Account for FREE
National Institutes of Health
3.5
based on 4 Reviews
About National Institutes of Health
Founded in1887 (138 yrs old)
India Employee Count--
Global Employee Count10k-50k
HeadquartersBethesda
Office Locations
--
Websitenih.gov
Primary Industry
--
Other Industries
Are you managing National Institutes of Health's employer brand? To edit company information,
claim this page for free
The National Institutes of Health (NIH), through its own research and the distribution of grants, seeks to understand disease inside and out. Part of the US Department of Health and Human Services, NIH is the government's main medical research entity. It comprises 27 institutes and centers covering every medical discipline, from general medical sciences to alternative therapies. The organization has some 6,000 scientists of its own and gives out at least 50,000 grants to researchers at more than 3,000 universities, hospitals, and research labs in all 50 states. Among its vast array of projects, NIH has supported efforts to develop an AIDS vaccine, map human genetic variation, and study avian flu.
Mission: NIH’s mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life and reduce illness and disability
Managing your company's employer brand?
Claim this Company Page for FREE
National Institutes of Health Ratings
based on 4 reviews
Overall Rating
3.5/5
How AmbitionBox ratings work?
5
2
4
1
3
0
2
1
1
0
Category Ratings
5.0
Salary
5.0
Skill development
4.2
Work-life balance
4.2
Work satisfaction
4.0
Company culture
4.0
Promotions
2.9
Job security
National Institutes of Health is rated 3.5 out of 5 stars on AmbitionBox, based on 4 company reviews.This rating reflects an average employee experience, indicating moderate satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
National Institutes of Health Reviews
Compare National Institutes of Health with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 3.5/5 based on 4 reviews | 4.0/5 based on 2.1k reviews | 4.1/5 based on 4.6k reviews | 4.3/5 based on 124 reviews |
Highly Rated for | Skill development Salary Work-life balance | Skill development Job security Work-life balance | Job security Skill development Company culture | Skill development Work-life balance Work satisfaction |
Critically Rated for | Job security | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | - | Work from office 86% employees reported | Work from office 80% employees reported | Work from office 83% employees reported |
Rating by Women Employees | - no rating available | 4.0 Good rated by 790 women | 4.1 Good rated by 1.6k women | 4.1 Good rated by 60 women |
Rating by Men Employees | - no rating available | 4.0 Good rated by 1.1k men | 4.1 Good rated by 2.4k men | 4.5 Good rated by 59 men |
Job security | 2.9 Poor | 3.9 Good | 4.1 Good | 3.4 Average |
View more
National Institutes of Health Salaries
National Institutes of Health salaries have received with an average score of 5.0 out of 5 by 4 employees.
Post Doctoral Fellow
(2 salaries)
Unlock
₹5.4 L/yr - ₹6.9 L/yr
Reactjs Developer
(1 salaries)
Unlock
₹10.4 L/yr - ₹13.3 L/yr
SSO
(1 salaries)
Unlock
₹0.2 L/yr - ₹0.2 L/yr
Senior Officer
(1 salaries)
Unlock
₹4.8 L/yr - ₹6.2 L/yr
Seles Executive
(1 salaries)
Unlock
₹5 L/yr - ₹6.3 L/yr
Data Entry Operator
(1 salaries)
Unlock
₹1.9 L/yr - ₹2.5 L/yr
Senior Research Fellow
(1 salaries)
Unlock
₹4.5 L/yr - ₹5.8 L/yr
Senior Developer
(1 salaries)
Unlock
₹12.6 L/yr - ₹16.1 L/yr
Software Engineer
(1 salaries)
Unlock
₹5.4 L/yr - ₹6.9 L/yr
Resource Person
(1 salaries)
Unlock
₹3.2 L/yr - ₹4.1 L/yr
National Institutes of Health News
View all
NCI employees can’t publish information on these topics without special approval
- Employees at the National Cancer Institute (NCI) have been instructed to flag manuscripts or communications that address "controversial, high profile, or sensitive" topics.
- The NCI provided internal guidance to review publications related to hot-button issues, including vaccines, fluoride, peanut allergies, and autism.
- The extent of the list and the requirement for review by a clearance team is unprecedented and unusual, according to anonymous NCI employees.
- All materials flagged by the employees must undergo scrutiny by officials at the National Institutes of Health and possibly the US Department of Health and Human Services.
Arstechnica | 11 Mar, 2025
Study Highlights Crucial Antibodies for Advancing a Universal Norovirus Vaccine
- Scientists from The University of Texas at Austin, the University of North Carolina at Chapel Hill, and the National Institutes of Health collaborated on a study unveiling potent antibodies for combating norovirus, a major cause of gastroenteritis globally.
- Their research, published in Science Translational Medicine, identified antibodies capable of neutralizing various norovirus strains, offering hope for a universal vaccine and therapeutic antibodies.
- Norovirus infects millions annually, posing a severe threat to vulnerable populations due to its genetic diversity and mutation capabilities.
- Through advanced molecular analysis, the team discovered broadly neutralizing antibodies from individuals in an experimental vaccine trial, showing efficacy against multiple norovirus strains.
- Particularly promising is the antibody VX22, which targets a unique viral site and neutralizes different genotypes, making it a strong candidate for vaccine development.
- The urgent need for a norovirus vaccine is emphasized by increasing cases, especially during winter, and the virus's prevalent transmission through contaminated sources.
- The identified antibodies not only hold promise for a vaccine but also for post-infection therapies, aiding individuals with compromised immune systems fighting norovirus.
- The ongoing research aims to refine vaccine design and verify findings across diverse populations, ensuring safety and efficacy for all demographics.
- The collaborative efforts and funding support from institutions like the NIH are propelling advancements in norovirus research, offering potential solutions for public health strategies.
- These significant findings bring optimism for combating norovirus, seeking to improve health outcomes and reduce the virus's impact on global health.
- With the hope of a viable vaccine becoming more tangible, ongoing research aims to enhance mitigation strategies against norovirus, fostering better health for at-risk populations.
Bioengineer | 6 Mar, 2025
Research Highlights Need for Personalized Approaches in Stroke Rehabilitation
- A groundbreaking study by Georgetown University Medical Center, in collaboration with MedStar Health and NIH, introduces an innovative brain imaging technique for stroke rehabilitation.
- The study focuses on assessing white matter tracts that relay signals to limbs, crucial for motor function recovery after a stroke.
- The novel imaging technique, diffusion tensor-based morphometry (DTBM), accurately maps and quantifies changes in white matter tracts.
- In living stroke survivors, DTBM enables the measurement of white matter tract atrophy, aiding in predicting motor recovery potential.
- Observable atrophy in critical brain cables strongly correlates with diminished chances for meaningful motor function recovery.
- The research article detailing these findings will be published in Neurology on March 3, 2025.
- Understanding recovery likelihood early can help tailor rehabilitation strategies effectively.
- Therapists can adjust approaches based on DTBM findings, supporting adaptive techniques for patients.
- Further studies are needed to solidify observations into standard rehabilitation protocols.
- The collaborative efforts underline a collective commitment to enhancing stroke recovery and quality of life.
Bioengineer | 4 Mar, 2025
Breakthrough ‘Ultra-Rapid’ Testing Reveals Cancer Genetics During Surgery
- Researchers at NYU Langone Health have developed a groundbreaking technology called Ultra-Rapid droplet digital PCR (UR-ddPCR) for near-instantaneous cancer cell identification during surgery, especially in neurosurgery.
- UR-ddPCR significantly enhances surgical precision by providing real-time molecular insights into tumor genetics, allowing surgeons to remove brain tumors more accurately.
- This technology can detect minuscule quantities of cancer cells, with the ability to identify as few as five malignant cells per square millimeter in just 15 minutes, unlike traditional methods that take hours.
- Efficient tumor cell removal is crucial in cancer surgery, and UR-ddPCR's rapid and accurate detection capabilities help optimize surgical strategies in real-time to prevent recurrence.
- The tool was validated in tests on glioma patients, demonstrating concordance with standard PCR methods and genetic sequencing, showing promise for in situ detection during surgery.
- UR-ddPCR reduces DNA extraction time significantly and improves sample processing protocols without compromising reliability, paving the way for enhanced surgical interventions.
- Integrating UR-ddPCR with stimulated Raman histology allows assessment of genetic mutations and tumor cell density, providing deeper insights for surgeons during procedures.
- While the technology shows promise, further refinements and clinical trials are needed before widespread implementation, with a focus on automating processes for complex surgeries and expanding applicability across malignancies.
- Supported by the National Institutes of Health and Bio-Rad, the collaborative effort behind UR-ddPCR exemplifies modern scientific progress aiming to transform patient care in oncology.
- As UR-ddPCR progresses towards clinical use, the healthcare industry anticipates its potential to revolutionize cancer resection and improve decision-making accuracy, ultimately aiming to enhance patient outcomes across various cancers.
Bioengineer | 26 Feb, 2025
Revolutionary Bone Marrow Transplant Offers Hope for Sickle Cell Disease Cure
- A clinical trial led by the Johns Hopkins Kimmel Cancer Center and other centers has shown promise in a new bone marrow transplant procedure for sickle cell disease.
- The trial focuses on reduced-intensity haploidentical bone marrow transplantation, allowing transplants from 'half-matched' donors, broadening the donor pool.
- Pre-transplantation regimen involves low-dose chemotherapy and total body irradiation, with post-transplant cyclophosphamide to reduce graft-versus-host disease risk.
- Results reveal 95% of participants survived two years post-transplant, with 88% cured, challenging gene therapy's efficacy.
- Dr. Richard Jones emphasizes comparable outcomes to gene therapy and the importance of accessible treatments for sickle cell disease.
- The procedure's safety and efficiency with half-matched donors refute common misconceptions, making it cost-effective compared to gene therapy.
- The study's implications extend to healthcare system efficiency, emphasizing the importance of tailored medical interventions for diverse populations.
- The diverse trial cohort, primarily Black individuals, highlights the need for equitable access to innovative therapies considering demographic disparities.
- Ongoing research collaboration and support from institutions like the NIH underscore the potential for widespread impact of haploidentical transplantation.
- Continued study is vital for long-term safety and efficacy evaluation, with a focus on educating healthcare professionals and patients for informed decision-making.
Bioengineer | 26 Feb, 2025
Unveiling Genetic Factors Behind Congenital Heart Disease
- A study by the Icahn School of Medicine uncovers genetic factors contributing to congenital heart disease (CHD), potentially transforming diagnosis and understanding of the condition.
- The research delves into digenic inheritance, highlighting how gene pairs interact to influence CHD risk, offering new insights into the genetic complexities of the disease.
- By analyzing exome sequencing data, ten gene pairs crucial in CHD development were identified, shedding light on hidden genetic liabilities.
- The study's innovative approach emphasizes the importance of genetic interactions beyond single-gene mutations for enhanced diagnostic yields in clinical genetics.
- Researchers aim to extend the digenic approach to other complex diseases, potentially unraveling genetic contributions in conditions with missing heritability.
- Collaboration and funding from institutions like the National Institutes of Health play a vital role in advancing genetic research and addressing complex disease mechanisms.
- The study bridges genetic research and clinical application, paving the way for improved therapies tailored to individual genetic profiles for congenital heart disease.
- Digenic models present promise in understanding disease development, indicating a shift towards comprehensive strategies to combat congenital conditions and complex diseases.
- The study's impact extends beyond congenital heart diseases, offering avenues for redefining diagnostic strategies and therapeutic interventions in genetic medicine.
- By advocating for innovation and collaboration in genetic studies, researchers hope to unravel further complexities in human genetics and propel the discipline to new healthcare frontiers.
- This research sparks dialogue within the scientific community, setting the stage for future inquiries into genetic interactions in disease mechanisms, shaping the landscape of clinical genetics.
Bioengineer | 20 Feb, 2025
Groundbreaking Implant Aids in Pinpointing Effective Treatments for Multiple Sclerosis in Mouse Models
- A groundbreaking study led by University of Michigan researchers explores a novel approach to understanding and treating primary progressive multiple sclerosis (PPMS) using a sponge-like implant.
- The research aims to slow or halt the progression of PPMS, known for its rapid advancement and severe disability outcomes within a short time frame.
- Utilizing nanoparticle-based treatment in mouse models showed potential in altering disease trajectories, preventing paralysis onset, and reducing symptom severity.
- Accessing live tissue samples from MS patients, particularly PPMS, poses a challenge, leading researchers to use a biodegradable implant to mimic the immune environment in mice.
- The implant allowed for the study of immune responses akin to those in the central nervous system, uncovering the significance of CC chemokines in disease progression.
- Injectable nanoparticles targeting overactive CC chemokines showed promising results in reducing disease activity and symptoms in treated mice.
- The study's findings offer insights into the mechanisms of PPMS and propose a dual therapeutic approach to halt disease progression and alleviate symptoms.
- The collaborative research, supported by prestigious institutions like the University of Michigan and the NIH, highlights the interdisciplinary efforts driving medical breakthroughs.
- Unlike current FDA-approved treatments relying on immunosuppression, the nanoparticle approach aims to correct immune over-activation while preserving essential functions and mitigating autoimmune attacks.
- While further research is required for clinical translation, the study indicates a potential shift in treating progressive MS through targeted therapeutic interventions.
- University of Michigan study's innovative use of engineered immunological niches represents a significant advancement in understanding and potentially treating primary progressive multiple sclerosis.
Bioengineer | 19 Feb, 2025
Revolutionary Gene-Editing Advance at Rice University Paves the Way for Enhanced Liver Disease Treatments and Beyond
- Rice University researchers have developed a cutting-edge gene-editing technique called Repair Drive, revolutionizing liver-targeted gene therapies and potentially expanding to other organs.
- Repair Drive significantly boosts the success rate of repairing liver cells, leading to improved liver regeneration and cell division in murine liver models.
- The method utilizes small interfering RNA (siRNA) to suppress the FAH gene temporarily and introduce therapeutic genes to enable only gene-edited cells to thrive and propagate.
- Gang Bao, a key figure in bioengineering at Rice University, highlights the importance of precision in gene editing and collaboration for scientific advancements.
- The collaborative efforts between Rice University and partners aim to enhance CRISPR/Cas9 techniques for more accurate and safe gene editing in diverse genetic disorders.
- The extensive research team, including members from various institutions, underscores the collective effort and expertise required for breakthroughs in gene therapy.
- Financial support from reputable organizations like the National Institutes of Health emphasizes the significant impact of this gene-editing research on public health.
- With pending patent applications, the commercial potential of Repair Drive technology presents opportunities for partnerships and advancements in medical treatment.
- The findings pave the way for enhanced gene therapies targeting liver disorders, showcasing the transformative potential of gene therapy and regenerative medicine.
- Collaboration and innovation remain crucial in advancing effective treatments for genetic disorders, holding promise for groundbreaking solutions that could revolutionize healthcare.
Bioengineer | 14 Feb, 2025
22 States Sue to Block New NIH Funding Policy, Court Issues Hold
- Twenty-two states secure victory in a lawsuit against the National Institutes of Health (NIH) concerning a policy change that would have reduced research funding at universities.
- The policy aimed to standardize indirect cost rates at 15 percent across all institutions, threatening budget shortfalls at research institutions nationally.
- Federal judge issues injunctions in response to legal challenges, blocking the policy change from taking effect immediately and applying retroactively to existing grants.
- Court orders NIH and Department of Health and Human Services to submit bi-weekly compliance reports to prevent circumvention of the injunction.
Tech Story | 12 Feb, 2025
22 states sue to block new NIH funding policy—court puts it on hold
- A coalition of 22 states has filed a suit to block the new NIH policy on indirect costs of research.
- The new policy, which reduces the indirect cost rate to 15 percent for every campus, would result in budget shortfalls for research universities.
- The lawsuit claims that the policy violates a long-standing law and a budget rider passed in response to a previous attempt to cut indirect costs.
- Judge Angel Kelley of the District of Massachusetts granted an injunction to prevent the policy from being applied in the states that have joined the lawsuit.
Arstechnica | 11 Feb, 2025
Powered by
Compare National Institutes of Health with
Max Healthcare
4.1
Columbia Asia
4.5
Narayana Health
4.2
Manipal Hospitals
4.1
Aster Dm Healthcare
3.8
Health Care Global Enterprises
4.1
Aravind Eye Hospital
4.2
HDFC Bank
3.9
Manappuram Finance
3.9
Emcure Pharmaceuticals
3.7
Kantar
3.5
Dentsu Aegis Network
3.4
Essel Group
4.2
International Flavors & Fragrances
3.8
Archirodon
3.9
China State Construction Engineering Corporation
3.9
WHSmith
4.4
ACCIONA
3.7
China Railway Construction Corporation
4.1
ABCL
4.0
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to National Institutes of Health
Indian Council of Medical Research
Healthcare
4.3
• 124 reviews
Apollo Hospitals
Healthcare
4.1
• 4.6k reviews
Fortis Healthcare
Healthcare / Pharma, Healthcare
4.0
• 2.1k reviews
Max Healthcare
Healthcare / Pharma, Healthcare
4.1
• 2.6k reviews
Columbia Asia
Healthcare
4.5
• 593 reviews
Narayana Health
Healthcare
4.2
• 1.5k reviews
Manipal Hospitals
Healthcare
4.1
• 1.4k reviews
Aster Dm Healthcare
Healthcare / Pharma, Healthcare
3.8
• 451 reviews
Health Care Global Enterprises
Healthcare
4.1
• 1.1k reviews
Aravind Eye Hospital
Healthcare / Pharma, Healthcare
4.2
• 107 reviews
HDFC Bank
Financial Services, Media & Entertainment / Publishing, Banking, Insurance, NBFC
3.9
• 39.9k reviews
Manappuram Finance
Financial Services, Media & Entertainment / Publishing, NBFC
3.9
• 4.2k reviews
National Institutes of Health FAQs
When was National Institutes of Health founded?
National Institutes of Health was founded in 1887. The company has been operating for 138 years.
Where is the National Institutes of Health headquarters located?
National Institutes of Health is headquartered in Bethesda.
What are the pros and cons of working in National Institutes of Health?
Working at National Institutes of Health comes with several advantages and disadvantages. It is highly rated for salary & benefits, skill development and work life balance. However, it is poorly rated for job security, based on 4 employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Helping over 1 Crore job seekers every month in choosing their right fit company
75 Lakh+
Reviews
5 Lakh+
Interviews
4 Crore+
Salaries
1 Cr+
Users/Month
Contribute to help millions
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2024 Info Edge (India) Ltd.
Follow us
